Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 4/7/2026 | $300.00 | Buy → Neutral | Citigroup | |
| 3/27/2026 | $610.00 | Buy | DZ Bank | |
| 12/11/2025 | $660.00 | Neutral → Buy | Citigroup | |
| 12/9/2025 | $685.00 | Buy | Goldman | |
| 12/8/2025 | $750.00 | Sector Weight → Overweight | KeyBanc Capital Markets | |
| 12/2/2025 | $670.00 | Overweight | Morgan Stanley | |
| 12/1/2025 | $670.00 | Hold → Buy | HSBC Securities | |
| 9/11/2025 | $550.00 | Equal Weight → Overweight | Barclays |
Citigroup downgraded Bio-Rad Labs from Buy to Neutral and set a new price target of $300.00
DZ Bank initiated coverage of Thermo Fisher with a rating of Buy and set a new price target of $610.00
Citigroup upgraded Thermo Fisher from Neutral to Buy and set a new price target of $660.00
AUSTIN, Texas, April 09, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: As regulatory demands intensify and production environments become more complex, pharmaceutical manufacturers are shifting beyond traditional quality assurance systems toward a new operational model: integrating artificial intelligence directly into manufacturing workflows as a continuous compliance layer. Rather than depending on retrospective audits and manual checks, AI-driven technologies are now capable of monitoring, validating and optimizing production processes in real time to ensure alignment with evolving Good Manufacturing Practice (GMP) requirements. This transformation is becoming increasingly vis
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced a strategic collaboration with Precision Health Research, Singapore (PRECISE) to advance the PRECISE-SG100K study, one of the region's most ambitious and diverse population-scale biobank initiatives. The collaboration reflects growing investments from national population studies looking to harness proteomics to drive insight into real-time disease biology for application in earlier detection, prevention and personalized care. As biobanks become central to national health strategies over the next decade, the integration of multi-omic platforms and AI-driven analytics is critical. When applied to
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2026 before the market opens on Thursday, April 23, 2026, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. The call will be webcast live on the "Investors" section of our website, www.thermofisher.com. You can access the conference call by dialing (833) 470-1428 within the U.S. or +1 (646) 844-6383 outside the U.S. The access code is 723173. The earnings press release and related information can also be found in that sec
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
DEFA14A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
DEF 14A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire
Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025. Mehta will lead Bio-Rad's global commercial strategy and execution, succeeding Mike Crowley, who is retiring after a distinguished 26-year career with the company. Mehta brings extensive leadership and commercial expertise in biopharmaceutical, life science research, and diagnostics markets to Bio-Rad. He joins from Labcorp, where he served as Senior Vice President, overseeing large-scale commercial operations for the company's West Divis
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2026 before the market opens on Thursday, April 23, 2026, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. The call will be webcast live on the "Investors" section of our website, www.thermofisher.com. You can access the conference call by dialing (833) 470-1428 within the U.S. or +1 (646) 844-6383 outside the U.S. The access code is 723173. The earnings press release and related information can also be found in that sec
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on April 15, 2026, to shareholders of record as of March 13, 2026. This reflects a 10% increase over the previous dividend payment of $0.43. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in thei
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. Norman Schwartz, Bio-Rad's Chief Executive Officer, stated: "2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are pleased with the initial market ado
SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)
SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)
SC 13G/A - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)